The Covid vaccine financial victors and casualties, from Novavax to Pfizer

Financial Success of Covid-19 Vaccines Not Reflected in Pharmaceutical Companies’ Stock Prices

It has been four years since the outbreak of Covid-19, which caused a global pandemic that resulted in the death of millions and brought the world to a halt. One of the most important aspects of controlling the spread of the virus has been the development of effective vaccines, which have played a critical role in saving countless lives.

The creation of vaccines by companies like Pfizer, BioNTech, and Moderna was a significant milestone in the fight against Covid-19. These vaccines generated incredible revenues, with total sales exceeding $80 billion and hundreds of millions of doses administered worldwide. However, despite their financial success, investors have not been as impressed.

Pfizer and BioNTech’s stock prices fell by 32% over the past five years, despite their enormous sales of vaccine. In contrast, AstraZeneca saw a 64% increase in its share price even though it hasn’t made any sales from its vaccine since last April. Even Merck, whose vaccine efforts failed twice, experienced a 56% increase in its stock price.

It is baffling how the financial success of these vaccines has not translated into positive gains for the companies producing them. Investors seem to be focusing on other factors when evaluating these pharmaceutical companies’ performance in relation to their Covid-19 vaccine sales.

Leave a Reply

Scarlett Johansson in discussions for lead role in upcoming ‘Jurassic World’ film Previous post Scarlett Johansson Joins Universal’s New Jurassic World Movie: A Return to Franchises after Marvel Success
Triple shooting near South Florida sports bar leaves 1 dead, 2 injured Next post Triple Shooting Near Player’s Sports Bar Leaves One Dead and Two Injured in North Lauderdale, Florida